20 13-20 15, the special fund of Shenzhen bio-industry development supported BGA non-invasive prenatal genetic testing technology for three years. The subsidy has been fully launched in Shenzhen, and the cost of non-invasive prenatal genetic testing does not exceed 1 105 yuan per person. After the three-year subsidy expires, it is expected to drop to 855 yuan, which means that the actual payment of the insured will gradually drop to 455 yuan.
Non-invasive prenatal genetic testing was stopped.
Although non-invasive prenatal genetic testing technology has been applied in many hospitals in China, on February 8, 20 14, China Food and Drug Administration and the National Health and Family Planning Commission jointly issued a notice, requiring that any medical institution should not carry out clinical application of gene sequencing before the relevant access standards and management norms are promulgated, and those that have been carried out should be stopped immediately. Because high-throughput sequencing technology is used for non-invasive prenatal genetic testing, and it is also within the scope of the "Notice", the clinical application of this technology is limited before the relevant access standards and management norms are issued.
The second generation of gene sequencing diagnostic products was approved for marketing.
After nearly half a year's suspension, prenatal genetic testing finally gained "legal status". After examination, China Food and Drug Administration approved the application of two second-generation gene sequencers and test kits of Huada Gene in "non-invasive prenatal genetic testing" on June 30th, that is, to detect the risk of Down syndrome and other genetic diseases of pregnant women and avoid birth defects of newborns. Today, BGI successfully registered the first second-generation gene sequencing diagnostic product in China, and the non-invasive prenatal genetic testing project with cooperative hospitals entered the restart stage.
A New Noninvasive Prenatal Gene Detection online to offline
On August 20th, 20 14, BGI and Shenzhen Jian 'an Hospital signed the Cooperation Agreement on Noninvasive Genetic Testing for Fetal 2 1- Trisomy Syndrome, which jointly promoted the new mode of non-invasive prenatal genetic testing "O2O", marking the beginning of BGI's cooperative development to the O2O platform.
The non-invasive prenatal genetic testing service (NIFTY) under the new online to offline only needs 880 yuan after enjoying the special subsidies from Shenzhen Municipal Government and Huada Gene. Compared with traditional channels, it is more convenient. You can make an appointment to the nearest hospital in advance, avoiding the trouble of queuing for registration, and will automatically get the Genebook pass, and automatically become the first batch of users of Huada Gene's big data and big health experience, and enjoy the first-time online inspection progress, result report, online consultation and other quality services.